WO1989002741A2 - Inhibiteurs de la transcriptase inverse de l'hiv servant au traitement du sida - Google Patents
Inhibiteurs de la transcriptase inverse de l'hiv servant au traitement du sidaInfo
- Publication number
- WO1989002741A2 WO1989002741A2 PCT/US1988/003114 US8803114W WO8902741A2 WO 1989002741 A2 WO1989002741 A2 WO 1989002741A2 US 8803114 W US8803114 W US 8803114W WO 8902741 A2 WO8902741 A2 WO 8902741A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- compound
- group
- salts
- immunodeficiency virus
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title description 6
- 239000003112 inhibitor Substances 0.000 title description 4
- 102000015084 HIV Reverse Transcriptase Human genes 0.000 title description 2
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- KJFMBFZCATUALV-UHFFFAOYSA-N Phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000011780 sodium chloride Substances 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 10
- WZZGVUSWZMBPPL-UHFFFAOYSA-N 3,7-dimethyl-4,6-dipropyl-1,9-dihydropyrido[3,2-g]quinoline-2,5,8,10-tetrone Chemical compound N1C(=O)C(C)=C(CCC)C2=C1C(=O)C(NC(=O)C(C)=C1CCC)=C1C2=O WZZGVUSWZMBPPL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000003115 biocidal Effects 0.000 claims abstract description 8
- LUYXWZOOMKBUMB-ONJZCGHCSA-N (1R,4aR,12aS)-3-acetyl-1-amino-4,4a,6,7-tetrahydroxy-8,11-dimethyl-12,12a-dihydro-1H-tetracene-2,5-dione Chemical compound C1=C(C)C(O)=C2C(O)=C(C([C@]3(O)C(O)=C(C([C@H](N)[C@@H]3C3)=O)C(=O)C)=O)C3=C(C)C2=C1 LUYXWZOOMKBUMB-ONJZCGHCSA-N 0.000 claims abstract description 7
- APOXLHGBQWCHJE-VKJLMELXSA-N (5S)-5-[(2R,3R,4S,5R,6R)-6-(acetyloxymethyl)-3-hydroxy-4-[(2R,4R,5R,6S)-5-hydroxy-4-methoxy-6-methyl-5-[(1S)-1-[(2S)-2-methylbutanoyl]oxyethyl]oxan-2-yl]oxy-5-[(Z)-2-isothiocyanatobut-2-enoyl]oxyoxan-2-yl]-2-amino-5-hydroxy-3,6-dioxocyclohexene-1-carboxyl Chemical compound C1[C@@H](OC)[C@@]([C@H](C)OC(=O)[C@@H](C)CC)(O)[C@H](C)O[C@H]1O[C@@H]1[C@H](OC(=O)C(=C\C)\N=C=S)[C@@H](COC(C)=O)O[C@@H]([C@]2(O)C(C(C(O)=O)=C(N)C(=O)C2)=O)[C@@H]1O APOXLHGBQWCHJE-VKJLMELXSA-N 0.000 claims abstract description 7
- QHKMTHBQSIKVAC-UHFFFAOYSA-N 2-[[5-[1-[3-[[bis(carboxymethyl)amino]methyl]-4-hydroxyphenyl]-3-oxo-2-benzofuran-1-yl]-2-hydroxyphenyl]methyl-(carboxymethyl)amino]acetic acid Chemical compound C1=C(O)C(CN(CC(O)=O)CC(=O)O)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C=C(CN(CC(O)=O)CC(O)=O)C(O)=CC=2)=C1 QHKMTHBQSIKVAC-UHFFFAOYSA-N 0.000 claims abstract description 7
- RWVUEZAROXKXRT-VQLSFVLHSA-N Maduramicin Chemical compound O1[C@@H](C)[C@H](OC)[C@@H](OC)C[C@H]1O[C@@H]1[C@H]([C@@]2(C)O[C@H](CC2)[C@@]2(C)O[C@]3(O[C@@H]([C@H](C)[C@@H](O)C3)[C@@H](C)[C@H]3[C@@H]([C@@H](OC)[C@H](C)[C@@](O)(CC(O)=O)O3)OC)CC2)O[C@@H]([C@@H]2[C@H](C[C@@H](C)[C@@](C)(O)O2)C)C1 RWVUEZAROXKXRT-VQLSFVLHSA-N 0.000 claims abstract description 7
- IIWPVOMPFBBVBL-UHFFFAOYSA-N methyl 6-formyl-4,7-dihydroxy-9-oxo-5H-phenazine-1-carboxylate Chemical compound N1C2=C(C=O)C(O)=CC(=O)C2=NC2=C1C(O)=CC=C2C(=O)OC IIWPVOMPFBBVBL-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 19
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 4
- 208000005721 HIV Infections Diseases 0.000 claims description 3
- VAYRRAYILPWSLZ-UHFFFAOYSA-J tetrasodium;2-[[5-[1-[3-[[bis(carboxylatomethyl)amino]methyl]-4-hydroxy-2-methyl-5-propan-2-ylphenyl]-3-oxo-2-benzofuran-1-yl]-2-hydroxy-6-methyl-3-propan-2-ylphenyl]methyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CC1=C(O)C(C(C)C)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C(=C(CN(CC([O-])=O)CC([O-])=O)C(O)=C(C(C)C)C=2)C)=C1C VAYRRAYILPWSLZ-UHFFFAOYSA-J 0.000 claims description 3
- UZNGGIDVCAOZQQ-UHFFFAOYSA-N 3H-2-benzofuran-1-imine Chemical compound C1=CC=C2C(=N)OCC2=C1 UZNGGIDVCAOZQQ-UHFFFAOYSA-N 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims 1
- 241000282412 Homo Species 0.000 abstract description 4
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000003612 virological Effects 0.000 description 5
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 4
- 102000033147 ERVK-25 Human genes 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 3
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- 229960002555 Zidovudine Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 201000000317 pneumocystosis Diseases 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000220479 Acacia Species 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 210000004698 Lymphocytes Anatomy 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 229940066842 Petrolatum Drugs 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 210000004027 cells Anatomy 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infection Diseases 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 206010020144 Histoplasmosis disseminated Diseases 0.000 description 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 108060006943 RdRp Proteins 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- OPGYRRGJRBEUFK-UHFFFAOYSA-L disodium;diacetate Chemical compound [Na+].[Na+].CC([O-])=O.CC([O-])=O OPGYRRGJRBEUFK-UHFFFAOYSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Definitions
- This invention is a novel treatment of patients infected with a human immunodeficiency virus.
- AZT zidovudine
- This invention is a method for treating a human infected with one or more than one strain of a human immunodeficiency virus which comprises administering an effective amount of a compound selected from the group consisting of lomofungin, paulomycin A, mycorhodin, antibiotic 357b, phenolphthalein diacetate, phenolphthalexon, thymophthalexon, U-64161, U-46768, U-18230, U-21052A, U-23278D, U-45483, U-57057, U-62455, U-12978E, U-42529, U-23034, diazaquinomycin A, maduramycin, and chelocardin or salts thereof, to the infected human.
- a compound selected from the group consisting of lomofungin, paulomycin A, mycorhodin, antibiotic 357b, phenolphthalein diacetate, phenolphthalexon, thymophthalexon, U-64161, U-46768, U-18230, U-210
- human immunodeficiency virus means human immunodeficiency virus type I, human immunodeficiency virus type II, or strains, apparent to one skilled in the art, which belong to the same viral family and which create similar physiological effects in humans as human immunodeficiency virus types I or II.
- dosage forms include oral formulations, such as tablets or capsules, or parenteral formulations, such as sterile solutions.
- an effective amount is from about 1 to 100 mg per kg per day.
- a typical unit dose for a 70 kg human would be from about 200 mg to 1000 mg taken one to four times per day.
- Either solid or fluid dosage forms can be prepared for oral administration.
- Solid compositions are prepared by mixing the compounds used to practice the method claimed in this invention with conventional ingredients such as talc, magnesium stearate, dicalcium phosphate, magnesium aluminum silicate, calcium sulfate, starch, lactose, acacia, methyl cellulose, or functionally similar pharmaceutical diluents and carriers.
- Capsules are prepared by mixing the compounds used to practice the method claimed in this invention with an inert pharmaceutical diluent and placing the mixture into an appropriately sized hard gelatin capsule.
- Soft gelatin capsules are prepared by machine encapsulation of a slurry of the compounds used to practice the method claimed in this invenition with an acceptable inert oil such as vegetable oil or light liquid petrolatum.
- Syrups are prepared by dissolving the compounds used to practice the method claimed in this invention in an aqueous vehicle and adding sugar, aromatic flavoring agents and preservatives.
- Elixirs are prepared using a hydroalcoholic vehicle such as ethanol, suitable sweeteners such as sugar or saccharin and an aromatic flavoring agent.
- Suspensions are prepared with an aqueous vehicle and a suspending agent such as acacia, tragacanth, or methyl cellulose.
- parenteral solutions are prepared by dissolving the compounds used to practice the method claimed in this invention in water and filter sterilizing the solution before placing in a suitable sealable vial or ampule.
- Parenteral suspensions are prepared in substantially the same way except a sterile suspension vehicle is used and the compounds used to practice the method claimed in this invention are sterilized with ethylene oxide or suitable gas before it is suspended in the vehicle.
- Patients to be treated would be those individuals: 1) infected with one or more than one strain of a human immunodeficiency virus as determined by the presence of either measurable viral antibody or antigen in the serum and 2) having either a symptomatic AIDS defining infection such as i) disseminated histoplasmosis, ii) isoporiasis, iii) bronchial and pulmonary candidiasis including pneumocystis pneumonia iv) non-Hodgkin's lymphoma or v) Kaposi's sarcoma and being less than sixty years old; or having an absolute CD4 lymphocyte count of less than 200/mm 3 in the peripheral blood.
- Treatment would consist of maintaining an inhibitory level of the compounds of this invention in the patient at all times and would continue until the occurrence of a second symptomatic AIDS defining infection indicates alternate therapy is needed.
- One thousand two-piece hard gelatin capsules for oral use, each capsule containing 50 mg of phenolphthalein diacetate, are prepared from the following:
- Phenolphthalein diacetate 50 gm Lactose 100 gm
- Example 2 Tablets One thousand tablets, each containing 50 mg of phenolphthalein diacetate, are prepared from the following:
- a sterile aqueous solution for parenteral intravenous injection containing 150 mg of phenolphthalein diacetate in one liter of solution is prepared from the following:
- the phenolphthalein diacetate sodium salt is sterilized, added to the sterile water, filled into sterile containers and sealed.
- Diazaquinomycin A which is rather insoluble in DMF or water, was tested as a suspension.
Abstract
Les composés décrits, qui sont sélectionnés dans un groupe composé de lomofungine, paulomycine A, mycorhodine, antibiotique 357b, diacétate de phénolphthaléine, phénolphthalexon, thymophthalexon, U-64161, U-46768, U-18230, U-21052A, U-23278D, U-45483, U-57057, U-62455, U-12978E, U-42529, U-23034, diazoquinomycine A, maduramycine et chélocardine ou de sels de ces composés peuvent être utilisés pour traiter des patients humains infectés avec une ou plusieurs souches d'un virus d'immunodéficience humain (HIV).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US107,123 | 1979-12-26 | ||
US10170687A | 1987-09-28 | 1987-09-28 | |
US101,706 | 1987-09-28 | ||
US10712387A | 1987-10-09 | 1987-10-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1989002741A2 true WO1989002741A2 (fr) | 1989-04-06 |
WO1989002741A1 WO1989002741A1 (fr) | 1989-04-06 |
Family
ID=26798544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1988/003114 WO1989002741A1 (fr) | 1987-09-28 | 1988-09-16 | Inhibiteurs de la transcriptase inverse de l'hiv servant au traitement du sida |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2527488A (fr) |
WO (1) | WO1989002741A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6800658B2 (en) * | 1997-11-20 | 2004-10-05 | Children's Medical Center Corporation | Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation |
US8754054B2 (en) | 2010-07-09 | 2014-06-17 | Albany Molecular Research, Inc. | Antibacterial compounds, methods of making them, and uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3359165A (en) * | 1966-11-02 | 1967-12-19 | Upjohn Co | Antibiotic lomondomycin and method of production |
-
1988
- 1988-09-16 WO PCT/US1988/003114 patent/WO1989002741A1/fr unknown
- 1988-09-16 AU AU25274/88A patent/AU2527488A/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4335311B2 (ja) | プロテアーゼインヒビターの生物学的及び抗ウイルス活性を改善する方法 | |
WO1989007939A2 (fr) | Coumarines permettant d'inhiber la transcriptase inverse chez les etres humains | |
US5047435A (en) | Antiviral compositions containing aromatic polycyclic diones and method for treating retrovirus infections | |
WO1992002530A1 (fr) | Hexa-n-(o-hydroxybenzyl) neomycine b destinee a l'inhibition des retrovirus humains et au traitement du sida | |
US5057325A (en) | Method of inhibiting replication of HIV with water-soluble melanins | |
DE68914990T2 (de) | Verfahren zur inhibierung der wirkung des menschlichen immunschwäche-virus (hiv) in vivo. | |
WO1989002741A2 (fr) | Inhibiteurs de la transcriptase inverse de l'hiv servant au traitement du sida | |
WO1989002741A1 (fr) | Inhibiteurs de la transcriptase inverse de l'hiv servant au traitement du sida | |
DE3881864T2 (de) | Antivirale zusammensetzungen mit aromatischen polycyclischen dionen sowie methode zur behandlung retroviraler infektionen. | |
Anand et al. | Interaction between rifabutin and human immunodeficiency virus type 1: inhibition of replication, cytopathic effect, and reverse transcriptase in vitro | |
US5153202A (en) | Method of inhibiting the activity of human immuno deficiency virus (HIV) in vivo | |
US5318979A (en) | Method of inhibiting the activity of cryptosporidium parvum | |
WO1989007384A2 (fr) | Composes a base d'iodure de 2-methylisoquinolinium utilises dans le traitement contre le sida | |
WO1989009056A1 (fr) | Composition antivirale contenant des diones aromatiques polycycliques et des analogues de nucleosides, et procede de traitement d'infections retrovirales | |
Ti et al. | Chloramphenicol concentrations in sera of patients with typhoid fever being treated with oral or intravenous preparation | |
CA2032748C (fr) | Methode d'inhibition de l'activite du virus de l'immunodeficience humaine (vih) in vivo | |
EP0352299A1 (fr) | Derives de rubradirine pour le traitement de l'infection hiv | |
WO1989009055A1 (fr) | Composition anti-virale contenant des diones polycycliques aromatiques et analogues de nucleoside, et procede de traitement d'infections retrovirales | |
CA2230086C (fr) | Procede ameliorant l'activite biologique et antivirale d'inhibiteurs de proteases | |
HOLLAND et al. | Characterization of oxyphenarsine as a potential antiviral agent for AIDS | |
WO1990014825A1 (fr) | Produit inhibiteur specifique de la transcriptase inverse de retrovirus, et son application comme medicament | |
JPH03209319A (ja) | 抗レトロウイルス薬 | |
JPH09503519A (ja) | イノシトール三燐酸の薬剤調製への使用 | |
Buckheit et al. | Significant Anti-HIV Activity of New Modified Poly Anionic Polymers in vitro | |
WO2000054771A1 (fr) | Utilisation de derives de 3,5-pyrazolidinedione pour combattre des infections virales |